Answer:
The uncompetitive and mixed inhibitors are not affected by the substrate concentration while inhibition by a competitive inhibitor can be overcome by increasing the concentration of the substrate.
Explanation:
A competitive inhibitor competes with the substrate for the active site of the enzyme. When the competitive inhibitor combines with the enzyme and forms the enzyme-inhibitor complex (EI complex), the substrate cannot bind to the active site. However, the inhibition by competitive inhibitor can be overcome by increasing the substrate concentration around the enzyme which in turn would allow the substrate to bind to the active site and the reaction would proceed.
On the other hand, an uncompetitive inhibitor binds to the site at the enzyme different from the active site. Once the ES complex is formed, the uncompetitive inhibitor joins the complex to inhibit the enzymatic activity.
Likewise, a mixed inhibitor also occupies a site on the enzyme distinct from the active site for the substrate. A mixed inhibitor binds to the enzyme or ES complex to inhibit the reaction.
Since the binding site for uncompetitive and mixed inhibitors are distinct from the substrate-binding site on the enzyme, increasing the substrate concentration can not overcome the inhibition.
Answer:
The answer is reciprocal chromosomal translocation
Explanation:
The Philadelphia chromosome (Ph) is the truncated chromosome 22 generated by the reciprocal translocation t(9;22)(q34;q11) and was first identified in 1960 in a patient with CML [3]. Translocation of the proto-oncogene tyrosine-protein kinase (ABL1) gene located on chromosome 9 to the breakpoint cluster region (BCR) gene located on chromosome 22 results in a BCR-ABL1 fusion gene on the Ph [4, 5]. Three BCR-ABL1 fusion gene hybrids encode BCR-ABL1 protein isoforms p210, p190, and p230, which have persistently enhanced tyrosine kinase (TK) activity. These aberrantly activated kinases disturb downstream signaling pathways, causing enhanced proliferation, differentiation arrest, and resistance to cell death [6, 7]. Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL1 protein are the most successful targeted therapy for Ph-positive leukemia.
Meiosis is the process of making sex cells(haploid cells). This is the main component of reproduction. Therfore, the greatest benefit is reproduction.
Meiosis I is dedicated to forming two Haploid(half chromosome) cells bby separating each pair of chromosomes (one of each type in each cell) and the recombination, or shuffling of genes on each chromosome with its pair by crossing over, While Meiosis II is meant to split the individual chromatids in the haploid cells to create a total or 4 daughter cells
Hope this helps! :)
